Delivery Order SPE2DB25D3201-SPE2DB25FNUFD
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,174.80 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by November 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $22,349.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract was competitively awarded without set-aside designation and is scheduled for completion by October 16, 2025. Performance will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a $14.4K delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,888.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, issued on November 13, 2025, with completion targeted for December 5, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger pharmaceutical supply agreement. This award will be performed at the contractor's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,766.46 and is scheduled for completion by November 26, 2025. The award was issued on November 4, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,944.10 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This non-competitive delivery order was issued on November 13, 2025, with an ultimate completion date of December 5, 2025. The contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,823.64 for 50-unit vials of Xeomin, a botulinum toxin injection used for therapeutic and cosmetic applications. This firm fixed-price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, represents a non-competitive set-aside award issued under the company's larger indefinite delivery contract. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $10,057.32 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 30, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,352.44 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin injection used for medical and therapeutic purposes. The contract, awarded on November 6, 2025, with an ultimate completion date of December 1, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $12,851.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The company...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNUFDDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,190.55 on June 26, 2025, for the supply of Xeomin 100 Unit Vials, a botulinum toxin product used in medical and surgical applications. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. This award demonstrates the company's continued role as a critical pharmaceutical distributor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 6/26/25 |